Grab Holdings Ltd. vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? Grab Holdings Ltd. trades at $3.13 (market cap $12.72B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.32 (market cap $2.27B). The key difference: Grab Holdings Ltd. is far larger — about 5.6× SELLAS Life Sciences Group Inc. Common Stock's market cap, and SELLAS Life Sciences Group Inc. Common Stock is trading nearer its 52-week high, Grab Holdings Ltd. nearer its low. Which is the better fit depends on your goals.
| GRAB | SLS | |
|---|---|---|
Market Cap | $12.72B | $2.27B |
Volume | 65,352,859 | 4,179,659 |
Sector | Technology | Health |
52-Week High | $6.17 | $15.46 |
52-Week Low | $2.80 | $1.39 |
Typical Hold Time | 94 Days | — |
Enterprise Value | $8.46B | $2.14B |
Signals from Pluang's Aura AI — not financial advice
GRAB trades at $3.08, up 0.33% with bearish technical signals but strong fundamentals. The company achieved profitability in 2025 with $268M net income and has beaten earnings estimates for three consecutive quarters. Recent news highlights a $30M CEO share purchase and acquisition of Atome Financial, signaling management confidence and financial services expansion.
GRAB presents a turnaround story with improving profitability and analyst support (91.7% buy ratings), though technical indicators remain bearish. Key risks include aggressive capital deployment and regional regulatory challenges. The stock offers growth potential but requires monitoring of execution risks and competitive pressures in Southeast Asia.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Grab Holdings Limited operates as a holding company. The Company, through its subsidiaries, develops delivery management, mobility, financial services, and enterprise software solutions. Grab Holdings serves customers worldwide.
Read more on GRAB →SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →